logo-loader

ValiRx Plc enjoying strong industry interest in its cancer treatments

Published: 13:01 19 Jul 2018 BST

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio.

Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship VAL401 lung cancer candidate.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

1 hour, 21 minutes ago